Pmv Pharmaceuticals Inc - Asset Resilience Ratio
Pmv Pharmaceuticals Inc (PMVP) has an Asset Resilience Ratio of 64.31% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PMVP PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Pmv Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Pmv Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Pmv Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pmv Pharmaceuticals Inc (PMVP) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $74.96 Million | 64.31% |
| Total Liquid Assets | $74.96 Million | 64.31% |
Asset Resilience Insights
- Very High Liquidity: Pmv Pharmaceuticals Inc maintains exceptional liquid asset reserves at 64.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pmv Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Pmv Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Pmv Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.31% | $74.96 Million | $116.56 Million | -2.91pp |
| 2024-12-31 | 67.22% | $128.58 Million | $191.29 Million | +1.64pp |
| 2023-12-31 | 65.58% | $165.35 Million | $252.15 Million | +16.46pp |
| 2022-12-31 | 49.11% | $132.76 Million | $270.31 Million | +11.51pp |
| 2021-12-31 | 37.61% | $124.70 Million | $331.57 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $365.53 Million | -- |
| 2019-12-31 | 27.38% | $28.21 Million | $103.03 Million | -22.42pp |
| 2018-12-31 | 49.80% | $31.60 Million | $63.46 Million | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as … Read more